Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics, Inc (ELTX)
:ELTX
Total Valuation
Elicio Therapeutics has a market cap or net worth of $79.77M. The enterprise value is $63.49M.
Market Cap$79.77M
Enterprise Value$63.49M
Share Statistics
Elicio Therapeutics has 15.95M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15.95M
Owened by Insiders35.35%
Owened by Instutions0.34%
Financial Efficiency
Elicio Therapeutics’s return on equity (ROE) is -3.09 and return on invested capital (ROIC) is -195.43%.
Return on Equity (ROE)-309.46%
Return on Assets (ROA)-129.65%
Return on Invested Capital (ROIC)-195.43%
Return on Capital Employed (ROCE)-205.67%
Revenue Per Employee$0
Profits Per Employee-$1,094,250
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicio Therapeutics is -1.20. Elicio Therapeutics’s PEG ratio is 0.05.
PE Ratio-1.20
PS Ratio0.00
PB Ratio3.71
Price to Fair Value3.71
Price to FCF-1.29
Price to Operating Cash Flow-1.29
PEG Ratio0.05
Income Statement
In the last 12 months, Elicio Therapeutics had revenue of $0.00 and earned -$35.02M in profits. Earnings per share was -$2.96.
Revenue$0.00
Gross Profit-$579.00K
Operating Income-$30.66M
Pretax Income-$35.02M
Net Income-$35.02M
EBITDA-34.06M
Earnings Per Share (EPS)-2.96
Cash Flow
In the last 12 months, operating cash flow was -$29.29M and capital expenditures -$42.00K, giving a free cash flow of -$29.29M billion.
Operating Cash Flow-$29.29M
Free Cash Flow-$29.29M
Free Cash Flow per Share-$1.84
Dividends & Yields
Elicio Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-77.69%
Earnings Yield-83.46%
Stock Price Statistics
Beta0.57
52-Week Price Change-45.83%
50-Day Moving Average7.65
200-Day Moving Average5.64
Relative Strength Index (RSI)23.49
Average Volume (3m)42.28K
Important Dates
Elicio Therapeutics upcoming earnings date is May 14, 2025, Before Open.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend Date―
Financial Position
Elicio Therapeutics as a current ratio of 1.67, with Debt / Equity ratio of 0.61
Current Ratio1.67
Quick Ratio1.67
Debt to Market Cap0.00
Net Debt to EBITDA0.18
Interest Coverage Ratio-33.75
Taxes
In the past 12 months, Elicio Therapeutics has paid $2.00K in taxes.
Income Tax$2.00K
Effective Tax Rate0.00%
Enterprise Valuation
Elicio Therapeutics EV to EBITDA ratio is -1.10, with an EV/FCF ratio of -1.10.
EV to Sales0.00
EV to EBITDA-1.10
EV to Free Cash Flow-1.10
EV to Operating Cash Flow-1.11
Balance Sheet
Elicio Therapeutics has $26.02M in cash and marketable securities with $6.21M in debt, giving a net cash position of -$19.80M billion.
Cash & Marketable Securities$26.02M
Total Debt$6.21M
Net Cash-$19.80M
Net Cash Per Share-$1.24
Tangible Book Value Per Share$2.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elicio Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside120.00%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast27.65%